Effect of antenatal tocolysis on neonatal outcomes

Objective: Detail adverse neonatal effects in pregnancies treated with indomethacin (I), magnesium sulfate (M) or nifedipine (N). Methods: Women in acute preterm labor with cervical dilatation 1-6-cm were randomized to receive one of three first-line tocolytic drugs. Results: There were 317 neonates (I = 103, M = 95, N-=-119) whose mothers were treated with tocolytic therapy. There was no difference in gestational age at randomization (average 28.6 weeks' gestation) or at delivery (31.6 weeks' gestation, p-=-0.551), birth weight (p = 0.871) or ventilator days (p = 0.089) between the three groups. Neonatal morbidity was not different between the three groups; respiratory distress syndrome (p-=-0.086), patent ductus arteriosus (p-=-0.592), sepsis (p-=-0.590), necrotizing enterocolitis (p = 0.770), intraventricular hemorrhage (p = 0.669) and periventricular leukomalacia (p-=-0.124). Conclusions: There were no statistically significant differences between the three tocolytics as far as composite neonatal morbidity or mortality was concerned.